S&P 5007,489.72▲0.7% Nasdaq25,373.85▲1.0% Dow52,485.03▲0.5% Russell 2K2,931.34▼0.5% 10-Yr4.75%+8bp VIX15.99−1.10 WTI$86.80▲3.8% Gold$4,098.60▼0.0% EUR/USD1.153▲0.5% BTC$62,930▼2.8% Nikkei61,867▲0.7%
At close · Fri, Jul 31, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Novo Nordisk shares fall after Phase 3 trial failure

Novo Nordisk shares fall after Phase 3 trial failure

Reported · Written up by our desk · Previews

Novo Nordisk’s stock fell on Friday after the company announced a Phase 3 trial failure, according to MarketWatch.

The news adds to investor concerns about the Danish healthcare company, after the trial outcome raised doubts about its broader pipeline.

← Newer storyAdam America and Stellar complete refi of 134-unit St. Cloud BTR proj…

More like this

EarningsAnalyst Report Focuses on Flex Ltd
EarningsAmazon, Microsoft and Alphabet add nearly $1.5 trillion in value
EarningsBanc of California targets higher NIM after balance sheet changes
EarningsNovo Nordisk shares slide after heart drug trial fails to show benefit
EarningsQuantum firms face Q2 earnings test after steep YTD declines

Sources

MarketWatchNovo Nordisk’s stock slumps after failed trial , adding to the company’s woes
MarketWatchNovo Nordisk’s stock slumps after failed trial , adding to the company’s woes

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.